文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性的基因治疗:一项1期随机剂量递增试验的三年随访

Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial.
PubMed 文献 · Am J Ophthalmol · 2017-02-27

这项1期剂量递增试验评估了视网膜下注射rAAV.sFlt-1治疗新生血管性年龄相关性黄斑变性(湿性AMD)36个月的安全性。8例晚期、既往接受过治疗的湿性AMD受试者按3:1随机分配至治疗组和非基因治疗对照组,治疗组分别接受低剂量(1×10^10载体基因组)或高剂量(1×10^11载体基因组)注射。36个月随访期间未观察到眼部或全身安全性信号,探索性数据分析提示湿性AMD病情稳定。

要点

  • 视网膜下注射rAAV.sFlt-1联合睫状体平坦部玻璃体切除术在该队列中耐受良好。
  • 36个月长期随访期间未观察到眼部或全身安全性信号。
  • 探索性数据分析提示36个月期间湿性AMD病情稳定。

核心结论

  • 视网膜下递送rAAV.sFLT-1耐受良好,并在至第36个月时展现出良好的安全性特征。
  • 因此,rAAV.sFLT-1可被安全地考虑用于未来湿性AMD治疗的评估。

研究设计与样本

  • 1期剂量递增试验,8例晚期、既往接受过治疗的湿性AMD受试者按3:1随机分配至治疗组和非基因治疗对照组。
  • 治疗组中3例接受低剂量(1×10^10载体基因组)rAAV.sFLT-1视网膜下注射,3例接受高剂量(1×10^11载体基因组)rAAV.sFLT-1视网膜下注射。
  • 入组条件为年龄≥65岁、湿性AMD、研究眼最佳矫正视力(BCVA)10/200至20/80且对侧眼20/200或更好。
  • 研究监测至第12个月主要终点为每月一次,随后在第18个月和第36个月进行方案驱动的随访访视。
  • 所有受试者在基线和第4周接受玻璃体腔内雷珠单抗注射,后续访视根据活动性湿性AMD的预设标准决定是否重复注射。

主要发现

  • 8例受试者中6例完成了36个月研究。
  • 视网膜下注射联合睫状体平坦部玻璃体切除术在该队列中耐受良好。
  • 长期随访期间未观察到眼部或全身安全性信号。
  • 探索性数据分析提示36个月期间湿性AMD病情稳定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the safety of rAAV.sFlt-1 subretinal injection in neovascular age-related macular degeneration (wet AMD) over 36 months. DESIGN: Phase 1 dose escalation trial. METHODS: Eight subjects with advanced, treatment-experienced wet AMD were randomly assigned (3:1) to treatment and non-gene therapy control groups. Eligible subjects were ≥65 years, had wet AMD, and had best-corrected visual acuity (BCVA) 10/200 to 20/80 in the study eye and 20/200 or better in the other eye. Three of the treatment group subjects received low-dose (1 × 1010 vector genomes) and 3 high-dose (1 × 1011 vector genomes) rAAV.sFLT-1 via subretinal injection. Study monitoring was monthly to the primary endpoint at month 12 and then protocol-driven follow-up study visits were conducted at months 18 and 36. All subjects received intravitreal ranibizumab at baseline and at week 4, and retreatment injections at subsequent visits based on prespecified criteria for active wet AMD. The primary endpoint was ocular and systemic safety, but exploratory data including BCVA, retinal center point thickness, and the number of ranibizumab retreatments at and between study visits were also analyzed. RESULTS: Six of the 8 subjects completed the 36-month study. Subretinal injection with pars plana vitrectomy was well tolerated in this cohort. No ocular or systemic safety signals were observed during the long-term follow-up period. Exploratory data analysis suggests stability of wet AMD over the 36-month period. CONCLUSIONS: Subretinal delivery of rAAV.sFLT-1 was well tolerated and demonstrated a favourable safety profile through month 36. Thus, rAAV.sFLT-1 could be safely considered for future evaluation in the treatment of wet AMD.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Constable IJ, Lai CM, Magno AL, et al. Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial. Am J Ophthalmol. 2017. PMID: 28245970. doi:10.1016/j.ajo.2017.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。